Quick Look at Meta-Studies with the Best Treatment Outcomes for Prophylaxis of C19 and Early Stage C19 Disease

A couple of questions before we kick off.

• At what point does the SARS-COV2 virus morph into the CoVID-19 disease? What are the characteristics of the people where this “morphing” occurs?

• Almost all attention is paid to those that are worst impacted by the SARS-COV2 virus and C19 disease. What are the common characteristics of those that were NOT impacted? (US “case rate” = 30% over almost 3 years - 10% per annum - , infection rate maybe 2 or 3 times that, certainly the “exposure rate” is probably more than 90% for the more recent C19 Omicron variants).

• What is the difference between the mRNA spike protein that the body manufactures from C19 mRNA injections and the “natural/wild” spike protein? How does testing distinguish between the two? Are C19 “cases” inflated because the testing cannot distinguish between an injected generated spike protein and a natural/wild spike protein? Or do the tests not even look for C19 spike proteins?

• Why is “gain of function” solely researched for “bad stuff” and not “good stuff”?

• Can the entire human genome be created with CRISPr technology, rather than just “snipping” out the “bad DNA” and replacing ti with “good DNA?

Ok, using data from here:

COVID-19 early treatment: real-time analysis of 2,248 studies (c19early.org)

https://c19early.org/#fpall

This website compiles data from meta-studies covering  dozens of C19 treatments pus links to the actual studies themselves. A great resource.

H/t fellow SubStacker “&c” for pointing out the potential of Melatonin. I will be increasing oily fish like salmon and sardines plus upping my intake of pistachios and almonds when I remember plus maybe some extra berries!

Here is a table of the highest mortality reductions from studies with more than 7,500 patients across all studies. The website shows treatments with ≤3 studies with distinct authors or with <25 control events in grey.

The first one is mortality reduction via prophylaxis – note the >25% improvement filter combined with the 7,500 minimum patient filter.

This one shows mortality reduction for early treatment with the 7,500 patient minimum across all studies but this time with greater than 50% mortality improvement.

The cost/life saved is an interesting statistic. Across all stages of the C19 disease (prophylaxis, early to mid-stage and late stage) here are the cheapest and most expensive treatments per life saved.

The figures are, perhaps, more subjective than objective, but guess which are big pharma treatments and which are more “generic”.

Onwards!